The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.
ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.
Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data.
GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines.
Genentech's blockbuster follow-up shows promise in preliminary Phase III data